Inizio Ignite

AT & IT China 2020, to be held alongside CPhI & P-MEC China 2020, will showcase Intelligent Pharma High-tech solutions

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.
- Advertisement -

AT & IT China 2020, organized by Informa Markets and China Chamber of Commerce for Import & Export of Medicines & Health Products and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., to take place at the Shanghai New International Expo Centre on June 22-24, 2020 together with CPhI & P-MEC China 2020, will focus on automatic production, information system layout, network security, and the new trend of safety and lean manufacturing of the pharmaceutical industry.

China’s pharmaceutical industry has rapidly developed in the past decade with the gross output value increasing from RMB 667.9 billion to nearly RMB 3 trillion in 2017. In recent years, Chinese pharmaceutical industry is entering a brand-new era that focuses on quality and innovation with new policies for the implementation of generic drug consistency evaluation, acceleration of pharmaceutical product review and approval, etc.

Improvement of pharmaceutical equipment quality and stability and optimization of the pharmaceutical industry’s automation and information levels has become key factors for pharmaceutical enterprises to achieve quality assurance and improve innovation abilities. As a result, to meet the digital production transformation of the fast-growing pharmaceutical industry, more and more equipment suppliers have thrown themselves into intelligent equipment upgrading.

Automatic labeling technology boosting whole-process electronic traceability system implementation
AT & IT China 2020 will bring practice solutions that can realize global traceability systems to meet the demands for establishing electronic traceability information system for pharmaceutical product. Sunflower Technology, a Chinese enterprise that has entered the traceability industry early, will show product with new technology that combines high-speed accurate labeling and QR code data acquisition. The product will help enterprises tackle the technological difficulty in vaccines’ whole-process traceability to reduce labor force on the production line and increase productivity.

Intelligent sensor technology driving pharmaceutical production automation development
China’s sensor technology development level continues to improve while the global sensor industry rapidly grows. Shanghai Fine Automation Co., Ltd., an excellent representative in China’s sensor technology field, will display a new product exclusive to the pharmaceutical industry during AT & IT China 2020 – intelligent material/liquid level sensor. The sensor is the “SIS Impedance Spectroscopy Sensor” certified by the U.S. FDA, which has an impressive effect on sensing materials such as foamy fermentation liquid, thick extraction liquid, and can perfectly replace traditional floating ball and tuning fork switch.

AT & IT China 2020 will showcase automatic equipment, promote information systems and introduce production robots and share network security maintenance points with tens of thousands of pharmaceutical factory buyers.

For more information, please visit the official website: https://www.pmecchina.com/intelligent/en

Media contact: jennifer.yang@imsinoexpo.com, +86-21-3339 2533

 

Latest stories

Related stories

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.

Advancing Quality 4.0 Through Centralized Drug Knowledge 

Implementation of a unified data framework serves as the catalyst for modernizing pharmaceutical production, bridging the gap between legacy processes and intelligent automation. By consolidating disparate data streams into a cohesive repository, organizations achieve unprecedented visibility into critical quality attributes and process parameters. This transformation facilitates proactive risk mitigation and ensures that Good Manufacturing Practices are maintained through high-fidelity insights rather than retrospective analysis, ultimately fostering a culture of continuous improvement and operational excellence.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »